UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

SGLT2 Inhibitor–associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis

Clinical therapeutics, 2016-12, Vol.38 (12), p.2654-2664.e1

2016

Volltextzugriff (PDF)

Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)

Diabetes care, 2017-07, Vol.40 (7), p.943-950

2017

Volltextzugriff (PDF)

A Review of the Clinical Efficacy and Safety of Insulin Degludec and Glargine 300 U/mL in the Treatment of Diabetes Mellitus

Clinical therapeutics, 2017-08, Vol.39 (8), p.S12-S33

Woo, Vincent C., MD, FRCPC

2017

Volltextzugriff (PDF)

New Insulins and New Aspects in Insulin Delivery

Canadian journal of diabetes, 2015-08, Vol.39 (4), p.335-343

Woo, Vincent C., MD, FRCPC

2015

Volltextzugriff (PDF)

Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin

Diabetes, metabolic syndrome and obesity, 2017-01, Vol.10, p.317-332

2017

Volltextzugriff (PDF)

Sodium‐glucose co‐transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol

Diabetes, obesity & metabolism, 2019-10, Vol.21 (10), p.2192-2202

2019

Volltextzugriff (PDF)

Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes

Canadian journal of diabetes, 2020-02, Vol.44 (1), p.61-67

Woo, Vincent C.

2020

Volltextzugriff (PDF)

Dosing Irregularities and Self-Treated Hypoglycemia in Type 2 Diabetes: Results from the Canadian Cohort of an International Survey of Patients and Healthcare Professionals

Canadian journal of diabetes, 2014-02, Vol.38 (1), p.38-44

2014

Volltextzugriff (PDF)

856-P: Cardiovascular (CV) and Kidney Outcomes with Canagliflozin (CANA) According to Type 2 Diabetes (T2D) Treatment Targets at Baseline (BL) : Data from the CANVAS Program and CREDENCE

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists

Obesity reviews, 2024-03, Vol.25 (3), p.e13663-n/a

2024

Volltextzugriff (PDF)

A Study of Diabetes Teaching in Canadian Medical Schools

Canadian journal of diabetes, 2016-04, Vol.40 (2), p.149-151

2016

Volltextzugriff (PDF)

134-LB: Real-World Impact of Intermittently Scanned Continuous Glucose Monitoring on Hemoglobin A1c in People with Type 2 Diabetes in Canada That Use Basal Insulin—A Prospective Chart Review

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

964-P: Glycemic and Body Weight Responses to Oral Semaglutide in the PIONEER Trial Program

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

Dosing Irregularities and Self-Treated Hypoglycemia in Type 2 Diabetes: Results from the Canadian Cohort of an International Survey of Patients and Healthcare Professionals

Canadian journal of diabetes, 2015-11, Vol.39, p.19-25

2015

Volltextzugriff (PDF)

Use of flash glucose monitoring is associated with HbA1c reduction in type 2 diabetes managed with basal insulin in Canada: A real-world prospective observational study

Diabetes & vascular disease research, 2024-05, Vol.21 (3), p.14791641241253967-14791641241253967

2024

Volltextzugriff (PDF)

Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‐world setting

Diabetes, obesity & metabolism, 2018-05, Vol.20 (5), p.1316-1320

2018

Volltextzugriff (PDF)

Diabetes and Driving: 2015 Canadian Diabetes Association Updated Recommendations for Private and Commercial Drivers

Canadian journal of diabetes, 2015-10, Vol.39 (5), p.347-353

2015

Volltextzugriff (PDF)

Greater Combined Reductions of HbA1c ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators

Diabetes therapy, 2023-08, Vol.14 (8), p.1415-1425

2023

Volltextzugriff (PDF)

Acute Management and Outcomes of Patients with Diabetes Mellitus Presenting to Canadian Emergency Departments with Hypoglycemia

Canadian journal of diabetes, 2015-11, Vol.39, p.9-18

2015

Volltextzugriff (PDF)

IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test

Journal of diabetes science and technology, 2016-03, Vol.10 (2), p.389-397

2016

Volltextzugriff (PDF)

Acute Management and Outcomes of Patients with Diabetes Mellitus Presenting to Canadian Emergency Departments with Hypoglycemia

Canadian journal of diabetes, 2015-02, Vol.39 (1), p.55-64

2015

Volltextzugriff (PDF)

Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes

Expert review of endocrinology & metabolism, 2016-01, Vol.11 (1), p.7-19

2016

Volltextzugriff (PDF)

Dapagliflozin: where does it fit in the treatment of type 2 diabetes?

Expert opinion on pharmacotherapy, 2009-10, Vol.10 (15), p.2527-2535

Woo, Vincent C

2009

Volltextzugriff (PDF)

Considerations for Initiating a Sodium-Glucose Co-Transporter 2 Inhibitor in Adults With Type 2 Diabetes Using Insulin

Canadian journal of diabetes, 2018-02, Vol.42 (1), p.88-93

2018

Volltextzugriff (PDF)

Glycemic Improvement Throughout Hospital Stay on the Medical and Surgical Wards of a Teaching Hospital in Manitoba, Canada

Canadian journal of diabetes, 2012-10, Vol.36 (5), p.S30-S31

2012

Volltextzugriff (PDF)

1 – 25 von 217

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(200)
Mit Volltextzugriff
(197)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(138)
Life Sciences & Biomedicine
(119)
Humans
(110)
Female
(64)
Male
(64)
Middle Aged
(55)
Aged
(49)
Endocrinology & Metabolism
(46)
Adult
(41)
Diabetes
(29)
Biological And Medical Sciences
(28)
Diabetes Mellitus
(26)
Other
(24)
Risk Factors
(23)
Medical Sciences
(21)
Insulin
(20)
Treatment Outcome
(20)
Type 2 Diabetes
(20)
Diabetes Mellitus, Type 2 - Drug Therapy
(19)
Infectious Diseases
(18)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

SGLT2 Inhibitor–associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis

Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)

A Review of the Clinical Efficacy and Safety of Insulin Degludec and Glargine 300 U/mL in the Treatment of Diabetes Mellitus

New Insulins and New Aspects in Insulin Delivery

Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin

Sodium‐glucose co‐transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol

Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes

Dosing Irregularities and Self-Treated Hypoglycemia in Type 2 Diabetes: Results from the Canadian Cohort of an International Survey of Patients and Healthcare Professionals

856-P: Cardiovascular (CV) and Kidney Outcomes with Canagliflozin (CANA) According to Type 2 Diabetes (T2D) Treatment Targets at Baseline (BL) : Data from the CANVAS Program and CREDENCE

Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists

A Study of Diabetes Teaching in Canadian Medical Schools

134-LB: Real-World Impact of Intermittently Scanned Continuous Glucose Monitoring on Hemoglobin A1c in People with Type 2 Diabetes in Canada That Use Basal Insulin—A Prospective Chart Review

964-P: Glycemic and Body Weight Responses to Oral Semaglutide in the PIONEER Trial Program

Dosing Irregularities and Self-Treated Hypoglycemia in Type 2 Diabetes: Results from the Canadian Cohort of an International Survey of Patients and Healthcare Professionals

Use of flash glucose monitoring is associated with HbA1c reduction in type 2 diabetes managed with basal insulin in Canada: A real-world prospective observational study

Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‐world setting

Diabetes and Driving: 2015 Canadian Diabetes Association Updated Recommendations for Private and Commercial Drivers

Greater Combined Reductions of HbA1c ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators

Acute Management and Outcomes of Patients with Diabetes Mellitus Presenting to Canadian Emergency Departments with Hypoglycemia

IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test

Acute Management and Outcomes of Patients with Diabetes Mellitus Presenting to Canadian Emergency Departments with Hypoglycemia

Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes

Dapagliflozin: where does it fit in the treatment of type 2 diabetes?

Considerations for Initiating a Sodium-Glucose Co-Transporter 2 Inhibitor in Adults With Type 2 Diabetes Using Insulin

Glycemic Improvement Throughout Hospital Stay on the Medical and Surgical Wards of a Teaching Hospital in Manitoba, Canada

Suchergebnisse filtern